Cantor Fitzgerald Forecasts Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Cantor Fitzgerald lowered their FY2026 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will earn $9.05 per share for the year, down from their previous estimate of $9.40. Cantor Fitzgerald has a “Overweight” rating and a $125.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

Other research analysts have also issued reports about the company. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Royal Bank Of Canada upped their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Finally, Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $114.82.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $118.37 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a fifty-two week low of $72.89 and a fifty-two week high of $121.83. The stock’s 50-day moving average is $111.88 and its two-hundred day moving average is $108.42. The firm has a market cap of $146.87 billion, a P/E ratio of 23.58, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the firm posted $2.01 EPS. The business’s revenue was up 1.4% compared to the same quarter last year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the sale, the insider owned 117,168 shares of the company’s stock, valued at $13,009,163.04. This represents a 2.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $8,734,625 over the last 90 days. Insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management lifted its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $27,000. Finally, Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.